MedTrace Logo

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02077192 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2023-12-11

Study results available
· View outcomes & findings →

Summary

The primary objective of this study was to assess the long term safety of fostamatinib in subjects with persistent/chronic ITP

Conditions

  • Immune Thrombocytopenic Purpura

Interventions

DRUG

Fostamatinib Disodium

Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day

Sponsors & Collaborators

  • Rigel Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Rigel Pharmaceuticals, Inc. · Rigel Pharmaceuticals,Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2020-06-02
Completion
2020-06-02

Countries

  • United States
  • Australia
  • Austria
  • Bulgaria
  • Canada
  • Czechia
  • Denmark
  • Hungary
  • Italy
  • Netherlands
  • Norway
  • Poland
  • Romania
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02077192 on ClinicalTrials.gov